Líneas de investigación

  • Therapeutic aspects

    The following lines are mainly focussed on clinical and diagnostic features of HIV & co-infection:

    • HCV and HBV coinfection. Efficacy and safety of new direct-antiviral drugs (DAA) against HCV. Long- term follow up of patients treated with DAA. Strategies toward HCV eradication
    • Antiretroviral treatment: efficacy and safety of new antiretroviral drugs
    • Studies of resistance
    • New antiretroviral strategies
    • Primary HIV infection: eradication and functional cure strategies
    • Use of Tirosine Knase inhibitors as a new strategy for HIV cure
  • Clinical and diagnostic aspects

    • Pharmacogenomics and pharmacokinetics
    • Opportunistic diseases associated to HIV infection: tuberculosis, human papillomavirus, anal cancer
    • Solid organ transplantation in HIV-infected patients
    • Incidence and management of non-AIDS defining events including infections, cardiovascular diseases, frailty, cancer and accelerated aging.
    • Early diagnosis and treatment of HCV reinfection
    • Pregnancy and HIV
    • Impact evolution and prognostic factor of COVID-19 in HIV patients
    • Immunological response of HIV patients to SARS-CoV-2 vaccines
  • Basic and translational research

    • Immuno-pathogenesis of HIV infection and mechanisms of HIV control
    • Generation of new immunogens based on defective HIV-based vectors 
    • Development of new therapeutic vaccines platforms: dendritic cells and RNA-based vaccines
    • Preventive vaccines based on the envelope of Transmitted-Founder Viruses
    • Studies on the HIV reservoirs in different clinical situations. Impact of tumour events in the maintenance of viral reservoirs.
    • Impact of tumour events in the maintenance of viral reservoirs
    • Studies on the modulation of microbiota in HIV-infected patients
    • Studies on senescence in HIV patients: molecular mechanisms and clinical implication
  • Epidemiological research and public health

    • Epidemiological studies based on cohorts (PISCIS, ART-CC, COHERE, EuroSida. PROBE-C)
    • STDs in HIV-infected patients. Epidemiology, diagnosis, treatment, and prevention
    • Prevention strategies: PEP and PrEP
    • Sexualised drug use. Early diagnosis and treatment of HIV, HCV and other STI in this high risk population. 'Chemsex' multidisciplinary management
    • New health-care strategies: telemedicine, shared health-care unit with primary care and OPAT programs
    • HIV infection in adolescent population
    • Anal cancer prevention program in immunosuppressed individuals
    • Chemsex management in MSM population